Notably, none of the 27 patients in the bosutinib arm who had diarrhea at the time of discontinuation discontinued treatment solely because of this AE.
As this trial specific scenario would not occur in routine clinical practice, we censored data from patients who discontinued at the time of discontinuation in the primary survival analysis.
Patients who discontinued treatment were censored at the time of discontinuation.
Participants who discontinued for reasons unrelated to treatment were censored at the time of discontinuation.
If a patient discontinues prematurely, the outcome measures will be obtained at the time of discontinuation.
Patients who discontinued prematurely completed final visit (month 12) assessments at the time of discontinuation, followed by the 4-week follow-up.
The median ANC at the time of discontinuation of IVAMT was 400/mm, and in 28/199 episodes (14%), IVAMT were discontinued before the ANC rose to 100/mm.
One patient received 12 cycles, discontinued the study for an unrelated medical condition and, at the time of discontinuation, had an increase in tumour size not yet reaching disease progression.
The mean time of discontinuation was longer in the patients who show decreased response (245.8+268.2 vs. 117.9+149.8 days, p=.01).
It is therefore a matter of concern to identify which factors present at the time of discontinuation may help physicians in predicting successful cessation of RRT [22].
While this series was too small to find a statistically significant effect of topical corticosteroid on biopsy result, it may be prudent to discontinue topical corticosteroid prior to conjunctival biopsy to optimize biopsy yield, although the ideal length of time of discontinuation is yet to be determined.
